fda semaglutide news The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added FDA Warns Against Using Compounded

MellerFOCostaCDSQuadraMRMirandaVIAEugnioFDDa SilvaTJet al

A mixed model for repeated measurements was used to input any missing data from test subjects that discontinued treatment or required a dose of rescue medication

Zhu, Y., Zhu, X., Tang, C., Guan, X

Conclusion Gallbladder risk associated with GLP-1 therapy remains a clinically relevant but manageable consideration in 2026

Furue 2020)

Quick Stats, USA Weight Management Beverages USA Weight Management Beverages Sales Value (2025): $1.65 billion USA Weight Management Beverages Forecast Value (2035): $3.37 billion USA Weight Management Beverages Forecast CAGR: 7.4% Leading Product Category in USA Weight Management Beverages Industry: Protein-based RTD (47%) Source: Fact.MR (November 2025) He also points out a growing consumer acceptance of different organoleptic characteristics in their beverages